Close Menu

NEW YORK (GenomeWeb) – Startup PreCyte has received a two-year grant worth nearly $2 million from the National Institutes of Health to validate and optimize a technology that uses cultured cells to detect blood-based biomarkers for Alzheimer's disease.

With the Direct-to-Phase II Small Business Innovation Research grant, PreCyte aims to test the so-called Indicator Cell Assay Platform, or ICAP, in hundreds of blood samples from presymptomatic and early-stage Alzheimer's disease patients, as well as normal controls.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.